The PALEXIA site is organized into 3 sections: PALEXIA PR, PALEXIA IR and footer content. Get an overview of each section below.
Palexia® PR SmPC, July 2016.
Mehra M et al. The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis. J Med Econ. 2012; 15(2):245-52.
Baron R, et al. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Pain Pract. 2016; 16(5):580-99.
Baron R et al. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Trial. Pain Practice 2016; 16(5):600-619.
Data on File, Grünenthal GmbH 2016.
Tzschentke TM, et al. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014; 28(4):319-29.
Tzschentke TM et al. Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs of Today 2009; 45(7):483-96.
Gottschalk A et al. New Concepts in Acute Pain Therapy: Preemptive Analgesia. Am Fam Physician. 2001; 63:1979-1986.
Schröder W et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. J Pharmacol Exp Ther. 2011; 337(1):312-20.
Tzschentke TM et al. Tapentadol Hydrochloride. Drugs Future 2006; 31(12):1053-1061.
Benarroch EE. Descending monoaminergic pain modulation: Bidirectional control and clinical relevance. Neurology 2008; 71(3):217-21.
Sánchez del Águila M et al. Practical Considerations for the Use of Tapentadol Prolonged Release for the Management of Severe Chronic Pain. Clin Therap. 2015; 37(1):94-113.
Buynak R et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010; 11(11):1787-1804.
Gálvez R et al. Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study. Adv Ther. 2013; 30:229-259.
Afilalo M et al. Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study. Clin Drug Investig. 2010; 30:489-505.
Wild JE et al. Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain. Pain Pract. 2010; 10:416-42.
Steigerwald I et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012; 28:911-936.
Steigerwald I et al. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res. 2012; 5:121-138.
Steigerwald I et al. Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain. Clin Drug Investig. 2013; 33:607-619.
Schwittay A et al. Gewebetrau Tapentadol retard bei starken chronischen Schmerzen. J Pain Palliat Care Pharmacother. 2013; 27(3):225-234.